MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation

Kristin Dawson1, Reza Wakili, Balázs Ordög

  • 1Montreal Heart Institute Research Center, 5000 Belanger St E, Montreal, Quebec, H1T 1C8, Canada.

Circulation
|March 6, 2013
PubMed
Abstract

Insights

Congestive heart failure and atrial fibrillation reduce microRNA29b (miR29b) levels, promoting atrial fibrosis. Restoring miR29b may combat fibrotic remodeling in heart conditions.

Area of Science:

  • Cardiovascular Research
  • Molecular Biology
  • Biomarker Discovery

Background:

  • Congestive heart failure (CHF) induces atrial fibrotic remodeling, supporting atrial fibrillation (AF) maintenance.
  • MicroRNA29 (miR29) is a key regulator of extracellular matrix proteins.
  • Investigating miR29b in AF and CHF is crucial for understanding atrial fibrosis.

Purpose of the Study:

  • To examine miR29b expression changes in patients and animal models of AF and CHF.
  • To assess the role of miR29b in regulating atrial fibrotic tissue production.
  • To evaluate miR29b as a potential biomarker and therapeutic target.

Main Methods:

  • Induction of CHF in a canine model via ventricular tachypacing.
  • Measurement of atrial miR29b expression and extracellular matrix gene expression (COL1A1, COL3A1, fibrillin) in fibroblasts.
  • In vivo manipulation of miR29b levels using lentiviral and adenoassociated viral vectors.
  • Quantification of plasma miR29b levels in patients with CHF and/or AF.

Main Results:

  • Atrial miR29b expression significantly decreased within 24 hours of CHF induction in dogs.
  • miR29b knockdown in fibroblasts increased collagen and fibrillin expression; miR29b overexpression decreased them.
  • Plasma miR29b levels were markedly reduced in patients with CHF or AF, and even lower in those with both conditions.
  • miR29b knockdown in mice led to increased atrial collagen content.

Conclusions:

  • MiR29b plays a significant role in atrial fibrotic remodeling associated with CHF and AF.
  • Reduced miR29b levels are a hallmark of these cardiac conditions.
  • MiR29b holds potential as a diagnostic biomarker and a therapeutic target for atrial fibrosis.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...